Immunovant to Launch US Phase 3 Trial for Batoclimab in MG

Immunovant to Launch US Phase 3 Trial for Batoclimab in MG

315600

Immunovant to Launch US Phase 3 Trial for Batoclimab in MG

Immunovant is moving forward with its Phase 3 clinical trial in the U.S. to evaluate the investigational myasthenia gravis (MG) therapy batoclimab in the first half of this year. The announcement came after the company reached an agreement with the division of neurology within the U.S. Food and Drug Administration (FDA) regarding the trial — designed to evaluate alternate dosing regimens for both disease maintenance and flare-ups. “We believe we have a differentiating approach to…

You must be logged in to read/download the full post.